Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTX-022 in Cutaneous Venous Malformations
NCT06653842Phase 2Active, not recruiting
- Sponsor
- Palvella Therapeutics
- Start
- Dec 2024
- Primary completion
- Nov 2025
- Modality
- Polymer-based Nanoparticles, Transdermal Patches, Hydrogel Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QTORIN rapamycin in cutaneous venous malformation, sponsored by Palvella Therapeutics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 12 weeks. Started Dec 2024; status: active, not recruiting.
02
Drugs
QTORIN rapamycin
03
Conditions
cutaneous venous malformation
Beyond the preview
Go deeper on NCT06653842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06653842.